Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kiniksa Pharmaceuticals International PLC KNSA

Healthcare Biotechnology
Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its portfolio of immune-modulating assets, ARCALYST, abiprubart and mavrilimumab, is based on strong biologic rationale or... see more

Recent & Breaking News (NDAQ:KNSA)

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

GlobeNewswire November 26, 2024

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

GlobeNewswire November 12, 2024

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire October 29, 2024

Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted(TM) Campaign to Drive Awareness of Recurrent Pericarditis

GlobeNewswire October 28, 2024

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

GlobeNewswire October 22, 2024

NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted(TM) Campaign to Drive Awareness of Recurrent Pericarditis

GlobeNewswire October 1, 2024

Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

GlobeNewswire August 28, 2024

Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire July 23, 2024

Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024

GlobeNewswire July 16, 2024

Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren's Disease

GlobeNewswire July 9, 2024

Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis

GlobeNewswire June 24, 2024

Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative

GlobeNewswire June 17, 2024

Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire June 4, 2024

Sector Spotlight: Orphan Drug Developers With Significant Upside

TheNewsWire June 3, 2024

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

GlobeNewswire May 7, 2024

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire April 23, 2024

Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

GlobeNewswire April 16, 2024

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

GlobeNewswire April 2, 2024

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution

GlobeNewswire February 28, 2024

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

GlobeNewswire February 21, 2024